<DOC>
	<DOCNO>NCT01649999</DOCNO>
	<brief_summary>This study evaluate efficacy safety ASP015K monotherapy evaluate dose-dependent response ASP015K moderate severe Rheumatoid Arthritis ( RA ) subject give ASP015K 12 week .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ASP015K Moderate Severe Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>This Phase 2b , randomize , double-blind , parallel-group , placebo-controlled , dose-finding , monotherapy , multi-center study daily oral ASP015K match placebo subject moderate severe RA , without prior antirheumatic medication , regardless responsiveness medication . The study comprise 4-week Screening period , 12-week Treatment period 4-week Follow-up period . Subjects treatment group take ASP015K match placebo orally , daily , breakfast 12 week screen period .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subject receive full explanation study drug study advance , write informed consent participate study obtain subject himself/herself Outpatient RA diagnose accord 1987 revised criterion ACR least 6 month prior screen At screen subject active RA evidence follow : ≥ 6 tender/painful joint ; ≥ 6 swollen joint ; CRP ≥ 0.5 mg/dL ESR ≥ 28 mm/h.CReactive Protein ( CRP ) ≥ 0.8 mg/dL Erythrocyte Sedimentation Rate ( ESR ) ≥ 28 mm/hr Subject meet ACR 1991 Revised Criteria Classification Global Functional Status RA , Class I , II , III screen Positive tuberculin ( TB ) test within 90 day Screening Abnormal chest xray indicative acute chronic infectious process malignancy Receipt live live attenuate virus vaccination within 30 day prior first dose study drug Hepatitis B virus hepatitis C virus carrier history positive test human immunodeficiency virus ( HIV ) infection Any autoimmune rheumatic disease , Sjogren 's syndrome Previous history clinically significant infection illness ( require hospitalization require parenteral therapy ) within 90 day Screening visit , history illness would preclude participation study History malignancy , except successfully treat basal squamous cell carcinoma skin insitu carcinoma cervix Does meet specify washout criterion follow RA medication : etanercept , certolizumab , adalimumab , golimumab , infliximab tocilizumab , rituximab , abatacept , anakinra , methotrexate , sulfasalazine , hydroxychloroquine , gold , penicillamine leflunamide Previous intolerance Janus kinase ( JAK ) inhibitor Receipt intraarticular parenteral corticosteroid within 28 day prior first dose study drug Receipt plasma exchange therapy within 60 day prior start study drug Receipt investigational agent within 30 day 5 halflives , whichever longer , prior first dose study drug Receipt medication CYP3A substrates narrow therapeutic range within 14 day prior first dose study drug History heart failure , define New York Heart Association ( NYHA ) grade 3 great</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP015K</keyword>
</DOC>